Your session is about to expire
← Back to Search
SGLT2 Inhibitor for Weight Loss Maintenance in Obesity
Study Summary
This trial aims to help obese people lose weight and keep it off by using a medication that increases their resting energy expenditure.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a BMI of 30 or higher and lost 5% of my weight in the last 6 months without using weight loss drugs.I have smoked within the last year.I have a history of lung disease.I have Type I Diabetes.I am under 18 years old.I am not pregnant, breastfeeding, and I use effective birth control or practice abstinence.I have no known allergies or adverse reactions to empagliflozin.I am 18 years old or older.My kidney function is reduced, with a GFR under 60 and high protein in my urine.I have a history of heart disease, stroke, diabetes, or seizures.I am on medication for weight loss or taking drugs that cause weight loss.
- Group 1: Placebo Arm
- Group 2: Empagliflozin Arm
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this investigation include elderly individuals as participants?
"This research is recruiting participants that are of legal age and under the cap of 80 years old."
Are patients still able to register for this investigation?
"Reported on clinicaltrials.gov, this particular trial has ceased recruitment activities since its last update from May 22nd 2023. Despite that, 1149 other studies are now actively looking for participants to join their trials."
Am I eligible to partake in this medical research?
"To be accepted for this clinical trial, patients must have lost weight and fall between the ages 18 to 80. 24 participants will eventually partake in the study."
Is Empagliflozin Arm a hazard to individuals?
"With limited clinical data advocating for its efficacy but some supporting safety, Empagliflozin Arm has been assigned a score of 2."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger